tradingkey.logo

Theravance Biopharma Inc

TBPH
15.220USD
+0.560+3.82%
Cierre 11/03, 16:00ETCotizaciones retrasadas 15 min
766.49MCap. mercado
58.82P/E TTM

Theravance Biopharma Inc

15.220
+0.560+3.82%

Más Datos de Theravance Biopharma Inc Compañía

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.

Información de Theravance Biopharma Inc

Símbolo de cotizaciónTBPH
Nombre de la empresaTheravance Biopharma Inc
Fecha de salida a bolsaMay 16, 2014
Director ejecutivoMr. Rick E. Winningham
Número de empleados97
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 16
DirecciónUgland House, South Church Street
CiudadGEORGE TOWN
Bolsa de valoresNASDAQ Global Market Consolidated
PaísCayman Islands
Código postalKY1-1104
Teléfono16508086000
Sitio Webhttps://www.theravance.com/
Símbolo de cotizaciónTBPH
Fecha de salida a bolsaMay 16, 2014
Director ejecutivoMr. Rick E. Winningham

Ejecutivos de Theravance Biopharma Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.29M
-1.18%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
208.00K
-3.25%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
150.40K
-6.10%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
132.77K
-6.59%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%
Dr. Deepika R. Pakianathan, Ph.D.
Dr. Deepika R. Pakianathan, Ph.D.
Independent Director
Independent Director
58.06K
+22.46%
Ms. Susannah Gray
Ms. Susannah Gray
Independent Chairman of the Board
Independent Chairman of the Board
42.14K
+33.82%
Mr. Jeremy T. Grant
Mr. Jeremy T. Grant
Independent Director
Independent Director
28.54K
+59.52%
Mr. Dean Jonathan (Dean) Mitchell
Mr. Dean Jonathan (Dean) Mitchell
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Rick E. Winningham
Mr. Rick E. Winningham
Chief Executive Officer, Director
Chief Executive Officer, Director
1.29M
-1.18%
Dr. Aine Miller
Dr. Aine Miller
Senior Vice President - Development and Head of Ireland Office
Senior Vice President - Development and Head of Ireland Office
208.00K
-3.25%
Mr. Brett A. Grimaud
Mr. Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
150.40K
-6.10%
Mr. Aziz Sawaf
Mr. Aziz Sawaf
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
132.77K
-6.59%
Mr. Eran Broshy
Mr. Eran Broshy
Independent Director
Independent Director
91.20K
+13.22%
Mr. Donal O'Connor
Mr. Donal O'Connor
Independent Director
Independent Director
74.20K
+16.76%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
U.S.
64.38M
0.00%
Europe
0.00
0.00%
Por negocio
Por región
Sin datos

Estadísticas de accionistas

Actualizado: mié., 8 de oct
Actualizado: mié., 8 de oct
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Madison Avenue Partners LP
18.89%
Weiss Asset Management
14.81%
Newtyn Management, LLC
9.83%
BlackRock Institutional Trust Company, N.A.
6.54%
Irenic Capital Management LP
5.48%
Otro
44.45%
Accionistas
Accionistas
Proporción
Madison Avenue Partners LP
18.89%
Weiss Asset Management
14.81%
Newtyn Management, LLC
9.83%
BlackRock Institutional Trust Company, N.A.
6.54%
Irenic Capital Management LP
5.48%
Otro
44.45%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
59.08%
Investment Advisor
17.40%
Investment Advisor/Hedge Fund
12.71%
Individual Investor
4.57%
Research Firm
3.78%
Pension Fund
0.28%
Bank and Trust
0.09%
Insurance Company
0.03%
Otro
2.06%

Participación institucional

Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
289
47.06M
93.45%
-4.43M
2025Q2
288
48.49M
96.98%
-9.87M
2025Q1
306
49.02M
97.92%
-10.33M
2024Q4
307
49.22M
100.10%
-11.44M
2024Q3
311
50.46M
103.15%
-9.84M
2024Q2
312
51.86M
106.61%
-21.43M
2024Q1
304
56.26M
115.67%
-11.52M
2023Q4
301
56.96M
111.33%
-13.16M
2023Q3
314
59.36M
109.50%
-14.46M
2023Q2
331
61.03M
103.70%
-24.91M
Ver más

Actividad de los accionistas

Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Madison Avenue Partners LP
9.51M
18.89%
--
--
Jun 30, 2025
Weiss Asset Management
7.46M
14.81%
--
--
Jun 30, 2025
Newtyn Management, LLC
4.95M
9.83%
+192.60K
+4.05%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.29M
6.54%
+259.25K
+8.54%
Jun 30, 2025
Irenic Capital Management LP
2.76M
5.48%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
2.16M
4.28%
+76.97K
+3.70%
Jun 30, 2025
Park West Asset Management LLC
1.80M
3.57%
-5.16K
-0.29%
Jun 30, 2025
Winningham (Rick E)
1.29M
2.57%
-15.39K
-1.18%
Aug 20, 2025
Oasis Management Company Ltd.
1.12M
2.22%
--
--
Jun 30, 2025
State Street Investment Management (US)
1.04M
2.06%
-31.13K
-2.92%
Jun 30, 2025
Ver más

ETFs relacionados

Actualizado: dom., 2 de nov
Actualizado: dom., 2 de nov
Nombre
Proporción
Virtus LifeSci Biotech Products ETF
2.29%
Inspire Fidelis Multi Factor ETF
1.06%
Janus Henderson Small Cap Growth Alpha ETF
0.79%
Invesco NASDAQ Future Gen 200 ETF
0.51%
Global X Aging Population ETF
0.46%
ALPS Medical Breakthroughs ETF
0.44%
SPDR S&P Pharmaceuticals ETF
0.33%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.24%
iShares U.S. Pharmaceuticals ETF
0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
0.19%
Ver más
Virtus LifeSci Biotech Products ETF
Proporción2.29%
Inspire Fidelis Multi Factor ETF
Proporción1.06%
Janus Henderson Small Cap Growth Alpha ETF
Proporción0.79%
Invesco NASDAQ Future Gen 200 ETF
Proporción0.51%
Global X Aging Population ETF
Proporción0.46%
ALPS Medical Breakthroughs ETF
Proporción0.44%
SPDR S&P Pharmaceuticals ETF
Proporción0.33%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción0.24%
iShares U.S. Pharmaceuticals ETF
Proporción0.2%
SPDR SSGA US Small Cap Low Volatility Index ETF
Proporción0.19%

Dividendos

Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos

División de acciones

Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI